Lupin Announces Major New Manufacturing Facility in Coral Springs, Targeting 200+ Jobs

Global pharmaceutical firm Lupin has announced plans to invest approximately $250 million to build a new state‑of‑the‑art pharmaceutical manufacturing facility in Coral Springs, Florida. The project will span more than five acres and accommodate production of more than 25 critical respiratory medicines, including inhalers used to treat asthma and other pulmonary conditions.

This expansion builds on Lupin’s existing presence in Florida — including its U.S. headquarters and Advanced Inhalation Research Center — and is expected to generate over 200 long‑term, skilled jobs in Broward County by 2030. The company is partnering with state and local entities, including Florida Commerce/Select Florida, the City of Coral Springs, and the Greater Fort Lauderdale Alliance, to secure incentives and workforce development support.

For the local biotech ecosystem, Lupin’s project is significant because it anchors large‑scale pharmaceutical manufacturing in South Florida. While much regional activity has centered on early‑stage R&D, this expansion brings deep operational capacity and supply‑chain integration — infrastructure that can attract further industry players and support a broader spectrum of life‑science activity.

Lupin press release via PR Newswire